Bank of New York Mellon Corp Lowers Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Bank of New York Mellon Corp lowered its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 22.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 78,180 shares of the biotechnology company's stock after selling 22,024 shares during the period. Bank of New York Mellon Corp owned 0.29% of Arcturus Therapeutics worth $1,327,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARCT. Empire Life Investments Inc. increased its holdings in shares of Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after acquiring an additional 128,771 shares in the last quarter. Spire Wealth Management boosted its stake in shares of Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 10,746 shares during the last quarter. SG Americas Securities LLC grew its holdings in Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 3,705 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company's stock valued at $1,393,000 after acquiring an additional 47,824 shares during the period. Finally, Nordea Investment Management AB boosted its position in shares of Arcturus Therapeutics by 3.7% in the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company's stock worth $1,097,000 after purchasing an additional 2,335 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded up $0.05 during trading on Thursday, hitting $12.00. The stock had a trading volume of 262,113 shares, compared to its average volume of 451,735. Arcturus Therapeutics Holdings Inc. has a one year low of $11.60 and a one year high of $45.00. The stock has a 50 day simple moving average of $15.81 and a 200 day simple moving average of $17.92. The stock has a market capitalization of $325.44 million, a price-to-earnings ratio of -5.41 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). The business had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

ARCT has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. HC Wainwright lowered their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group reduced their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, March 10th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research report on Monday, March 10th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $59.20.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.